StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.
Separately, Benchmark reaffirmed a "hold" rating on shares of VolitionRx in a research note on Friday, August 16th.
View Our Latest Analysis on VNRX
VolitionRx Trading Up 20.9 %
Shares of VolitionRx stock traded up $0.14 during trading on Wednesday, reaching $0.81. The company's stock had a trading volume of 307,231 shares, compared to its average volume of 162,095. The stock has a 50-day moving average price of $0.68 and a two-hundred day moving average price of $0.68. The stock has a market capitalization of $75.06 million, a P/E ratio of -2.25 and a beta of 1.10. VolitionRx has a one year low of $0.43 and a one year high of $1.23.
Hedge Funds Weigh In On VolitionRx
A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its position in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company's stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is currently owned by institutional investors.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
